Abstract
The Cryptococcus neoformans species complex contains the most important agents of fungal meningoencephalitis. Therapeutic choices are limited and issues related to toxicity and resistance to antifungals have been described. The present study evaluated the inhibitory effect of the antifolate combinations sulfamethoxazole–trimethoprim (SMX/TMP) and sulfadiazine–pyrimethamine (SDZ/PYR) against planktonic cells and biofilms of C. neoformans and C. gattii. The influence of the antifolate combinations on the amphotericin minimum inhibitory concentration (MIC) of planktonic cells was also investigated. In addition, the effect of these combinations on the cellular ergosterol content of planktonic cells was studied. Strains of C. neoformans (n = 15) and C. gattii (n = 15) obtained from environmental or clinical sources were evaluated by the broth microdilution method. SMX/TMP and SDZ/PYR showed antifungal activity against free living cells and sessile cells of Cryptococcus spp. Moreover, planktonic cells showed increased susceptibility to amphotericin B after pre-incubation with sub-inhibitory concentrations of SMX/TMP or SDZ/PYR. The drug combinations SMX/TMP and SDZ/PYR were able to prevent the biofilm formation and showed inhibitory effect against mature biofilms of both species. Additionally, the study showed that antifolate drugs reduced the ergosterol content in C. neoformans and C. gattii planktonic cells. Our results highlight the antifungal potential of antifolate drugs.
Similar content being viewed by others
References
Lin X, Heitman J (2006) The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 60:69–105
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50(3):291–322
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4):525–530
Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363(9423):1764–1767
Varma A, Kwon-Chung KJ (2010) Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother 54(6):2303–2311
Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M (2005) Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56(6):1144–1147
Bii CC, Makimura K, Abe S, Taguchi H, Mugasia OM, Revathi G, Wamae NC, Kamiya S (2007) Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 50(1):25–30
Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ (2009) Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 53(7):2804–2815
Martinez LR, Mihu MR, Han G, Frases S, Cordero RJ, Casadevall A, Friedman AJ, Friedman JM, Nosanchuk JD (2010) The use of chitosan to damage Cryptococcus neoformans biofilms. Biomaterials 31(4):669–679
Steverding D, Evans P, Msika L, Riley B, Wallington J, Schelenz S (2012) In vitro antifungal activity of DNA topoisomerase inhibitors. Med Mycol 50(3):333–336
Verwer PE, Woodle MC, Boekhout T, Hagen F, Bakker-Woudenberg IA, van de Sande WW (2011) Cryptococcus and Trichosporon spp. are susceptible in vitro to branched histidine- and lysine-rich peptides (BHKPs). J Antimicrob Chemother 66(7):1649–1652
Martinez LR, Casadevall A (2007) Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol 73(14):4592–4601
Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J (2009) Our current understanding of fungal biofilms. Crit Rev Microbiol 35(4):340–355
Martinez LR, Casadevall A (2006) Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun 74(11):6118–6123
Martinez LR, Casadevall A (2006) Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 50(3):1021–1033
Robertson EJ, Wolf JM, Casadevall A (2012) EDTA inhibits biofilm formation, extracellular vesicular secretion, and shedding of the capsular polysaccharide glucuronoxylomannan by Cryptococcus neoformans. Appl Environ Microbiol 78(22):7977–7984
Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M (1986) Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurgery 18(3):373–375
Ingram CW, Haywood HB 3rd, Morris VM, Allen RL, Perfect JR (1993) Cryptococcal ventricular-peritoneal shunt infection: clinical and epidemiological evaluation of two closely associated cases. Infect Control Hosp Epidemiol 14(12):719–722
Banerjee U, Gupta K, Venugopal P (1997) A case of prosthetic valve endocarditis caused by Cryptococcus neoformans var. neoformans. J Med Vet Mycol 35(2):139–141
Johannsson B, Callaghan JJ (2009) Prosthetic hip infection due to Cryptococcus neoformans: case report. Diagn Microbiol Infect Dis 64(1):76–79
Cordeiro RA, Costa AK, Brilhante RS, de Lima RA, Castelo-Branco Dde S, Ribeiro JF, Monteiro AJ, Rocha FA, Sidrim JJ, Rocha MF (2011) PCR-REA as an important tool for the identification of Cryptococcus neoformans and Cryptococcus gattii from human and veterinary sources. Vet Microbiol 154(1–2):180–184
Enache-Angoulvant A, Chandenier J, Symoens F, Lacube P, Bolognini J, Douchet C, Poirot JL, Hennequin C (2007) Molecular identification of Cryptococcus neoformans serotypes. J Clin Microbiol 45(4):1261–1265
Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E; IberoAmerican Cryptococcal Study Group (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9(2):189–195
Hanafy A, Uno J, Mitani H, Kang Y, Mikami Y (2007) In vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species. Jpn J Med Mycol 48(1):47–50
Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—third edition. CLSI document M27-A3. CLSI, Wayne, PA
Cordeiro Rde A, Astete-Medrano DJ, Marques FJ, Andrade HT, Perdigão Neto LV, Tavares JL, de Lima RA, Patoilo KK, Monteiro AJ, Brilhante RS, Rocha MF, de Camargo ZP, Sidrim JJ (2011) Cotrimoxazole enhances the in vitro susceptibility of Coccidioides posadasii to antifungals. Mem Inst Oswaldo Cruz 106(8):1045–1048
Costa AK, Sidrim JJ, Cordeiro RA, Brilhante RS, Monteiro AJ, Rocha MF (2010) Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia 169(3):207–213
Moran GP, Pinjon E, Coleman DC, Sullivan DJ (2007) Analysis of drug resistance in pathogenic fungi. In: Kavanagh K (ed) Medical mycology: cellular and molecular techniques. Wiley, Hoboken, pp 93–113
Peeters E, Nelis HJ, Coenye T (2008) Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 72(2):157–165
Navarro-Martínez MD, Cabezas-Herrera J, Rodríguez-López JN (2006) Antifolates as antimycotics? Connection between the folic acid cycle and the ergosterol biosynthesis pathway in Candida albicans. Int J Antimicrob Agents 28(6):560–567
Hahn RC, Morato Conceição YT, Santos NL, Ferreira JF, Hamdan JS (2003) Disseminated paracoccidioidomycosis: correlation between clinical and in vitro resistance to ketoconazole and trimethoprim sulphamethoxazole. Mycoses 46(8):342–347
Brilhante RS, Fechine MA, Cordeiro Rde A, Rocha MF, Ribeiro JF, Monteiro AJ, de Lima RA, Mesquita JR, de Camargo ZP, Sidrim JJ (2010) In vitro effect of sulfamethoxazole–trimethoprim against Histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother 54(9):3978–3979
Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, Chen YM, Phanuphak P, Lee CK, Saphonn V, Oka S, Zhang F, Choi JY, Pujari S, Kamarulzaman A, Li PC, Merati TP, Yunihastuti E, Messerschmidt L, Sungkanuparph S; TREAT Asia HIV Observational Database (2012) Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc 15:1
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005) In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 43(8):3807–3810
Funding declaration
This work was supported by grants from the National Council for Scientific and Technological Development (CNPq; Brazil; Processes 302574/2009-3 and 562296/2010-7). We would like to thank the Mycology Laboratory of the Evandro Chagas Clinical Research Institute in Rio de Janeiro (IPEC/FIOCRUZ) for providing the reference strains from its cryptococcal culture collection.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Aguiar Cordeiro, R., Mourão, C.I., Rocha, M.F.G. et al. Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B. Eur J Clin Microbiol Infect Dis 32, 557–564 (2013). https://doi.org/10.1007/s10096-012-1774-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-012-1774-8